The activation of ERβ by a selective ERβ agonist diarylpropionitrile (DPN) increases the adhesion of breast cancer cells by enhancing the surface expression of integrin α1 and integrin β1 (53). This evidence concerns the gene ESR2 and breast carcinoma.